New clinical guidelines: "Thyrotoxicosis associated with diffuse goiter (Graves’ disease), nodular and multinodular goiter

In June 2025, updated clinical guidelines for the diagnosis and management of thyrotoxicosis were released in the Russian Federation, developed on the basis of current scientific evidence, real-world clinical practice, and international standards. The document highlights the most significant and conceptual shifts — both in diagnostic algorithms and therapeutic strategies — including priorities in pharmacological treatment, and criteria for surgical intervention and radioiodine therapy. A comparative analysis reveals the evolution of clinical reasoning and the ongoing standardization of care for patients with thyrotoxicosis in contemporary endocrinology.

The aim of this review is to enhance clinicians’ awareness and promote a critically informed, balanced, and personalized approach to implementing these clinical guidelines in the diagnosis and treatment of thyrotoxicosis.

1. Fadeyev VV, Abramova NA, Prokofiev SA, Gitel EP, Mel'nichenko GA, Dedov II. Thyroid-stimulating hormone receptor antibodies in the differential diagnosis of toxic goiter. Problems of Endocrinology. 2005;51(4):10-18. (In Russ.)] doi: https://doi.org/10.14341/probl200551410-18

2. Sviridenko NI, Likhvantseva VG, Belovalova IM, Sheremeta MS, Tabeeva KI. Anti-TSH receptor antibodies as predictors of the severity and outcome of endocrine ophthalmopathy in the patients presenting with Graves' disease. Problems of Endocrinology. 2011;57(2):23-26 (In Russ.)]. doi: https://doi.org/10.14341/probl201157223-26

3. Rapoport B, McLachlan SM. TSH receptor cleavage into subunits and shedding of the Asubunit; a molecular and clinical perspective. Endocr Rev. 2016; 37:114–134. doi: https://doi.org/10.1210/er.2015-1098

4. Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res. Clin Endocrinol Metab. 2012; 26(3):291–302. doi: https://doi.org/10.1016/j.beem.2011.10.002

5. Brix TH, Kyvik KO, Christensen K, Hegedus L: Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930–934. doi: https://doi.org/10.1210/jcem.86.2.7242

6. Inaba H, De Groot LJ, Akamizu T: Thyrotropin receptor epitope and human leukocyte antigen in Graves’ disease. Front Endocrinol. 2016;7:120. doi: https://doi.org/10.3389/fendo.2016.00120

7. Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015;64:82–90. doi: https://doi.org/10.1016/j.jaut.2015.07.009

8. Brix TH, Hansen PS, Kyvik KO, Hegedus L. Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med. 2000;160:661–666. doi: https://doi.org/10.1001/archinte.160.5.661

9. Manji N, Carr-Smith JD, Boelaert K, et al. Influences of age, gender, smoking and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab. 2006;91(12):4873-4880. doi: https://doi.org/10.1210/jc.2006-1402

10. Свириденко Н.Ю. Функциональная автономия при эндемическом зобе. Проблемы эндокринологии. 2005;1:40–42. doi: https://doi.org/10.14341/probl200551140-41

11. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26(10): 1343–1421. doi: https://doi.org/10.1089/thy.2016.0229

12. Rossijskaya associaciya endokrinologov. Nacional'nye rekomendacii: Tireotoksikoz s diffuznym zobom (diffuznyj toksicheskij zob, bolezn' Grejvsa–Bazedova), uzlovym/mnogouzlovym zobom. M.; 2014. (In Russ.)]

13. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, et al. Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 2011; 17(3): 456–520. doi: https://doi.org/10.4158/ep.17.3.456

14. Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003–2005. Clin Endocrinol. 2013;78: 768–776. doi: https://doi.org/10.1111/cen.12060

15. McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ ethnicity in US military personnel. JAMA. 2014;311:1563–1565. doi: https://doi.org/10.1001/jama.2013.285606

16. Sviridenko NYu. Tireotoksikoz. Nacional'noe rukovodstvo «Obshchaya vrachebnaya praktika» / pod redakciej red. I.N. Denisova, O.M. Lesnyak. M.: GEOTAR-Media; 2013. S. 677–689 (In Russ.)]

17. van de Ven AC, Netea-Maier RT, de Vegt F, Ross HA, Sweep FC, Kiemeney LA, Smit JW, Hermus AR, den Heijer M. Associations between thyroid function and mortality: the influence of age. Eur J Endocrinol. 2014;171(2):183–191. doi: https://doi.org/10.1530/EJE-13-1070

18. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6:431–443. doi: https://doi.org/10.1038/nrendo.2010.105

19. Dedov II, Kalashnikov VYu, Terekhin SA, Golovenko EN, Sviridenko NYu, Melkozerov KV, Parfenenkova AA, Kopylov FYu, Gribanova AV. Fatal'nyj spazm koronarnoj arterii u pacienta s tireotoksikozom. Kardiologiya. 2012;52(11):92–96 (In Russ.)]

20. Sviridenko NY, Tugeeva EF, Aripov MA, Buziashvili YuI. Cardiac functional reserve and left ventricular parameters in patients with diffuse toxic goiter after drug correction of euthyroidism with thiamazol. Problems of Endocrinology. 2009;55(3):21-24. (In Russ.)] doi: https://doi.org/10.14341/probl200955321-24

21. Sviridenko NYu, Belovalova IM, Sheremeta MS, Tabeeva KI, Remizov OV. Bolezn' Grejvsa i endokrinnaya oftal'mopatiya / Pod redakciej akademika RAN I.I. Dedova i akademika RAN G.A. Mel'nichenko. M.: MAI-PRINT; 2012. 143 s (In Russ.)]

22. Fadeyev V. Clinical Aspects of Thyroid Disorders in the Elderly Thyroid international. 2007;3:4–15

23. Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, Bandinelli S, Guralnik JM, Valenti G, Ferrucci L. Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the Chianti Area Study. J Am Geriatr Soc. 2013; 61:868–874

24. Sohn SY, Lee E, Lee MK, Lee JH. The Association of Overt and Subclinical Hyperthyroidism with the Risk of Cardiovascular Events and Cardiovascular Mortality: Meta-Analysis and Systematic Review of Cohort Studies. Endocrinol Metab (Seoul). 2020;35(4):786–800. doi: https://doi.org/10.3803/EnM.2020.728

25. Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055–2065. doi: https://doi.org/10.1001/jama.2015.5161

26. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724–734. doi: https://doi.org/10.1038/nrendo.2013.193

27. Kahaly GJ, Olivo PD. Graves’ disease. N Engl J Med. 2017;376(2): 184. doi: https://doi.org/10.1056/NEJMc1614624

28. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107–113. doi: https://doi.org/10.1016/j.autrev.2012.07.003

29. Kahaly GJ, Diana T. TSH receptor antibody functionality and nomenclature. Front Endocrinol. 2017;8:28. doi: https://doi.org/10.3389/fendo.2017.00028

30. Kiefer FW, Klebermass-Schrehof K, Steiner M, Worda C, Kasprian G, Diana T, Kahaly GJ, Gessl A. Fetal/neonatal thyrotoxicosis in a newborn from a hypothyroid woman with Hashimoto thyroiditis. J Clin Endocrinol Metab. 2017;102(1):6–9. doi: https://doi.org/10.1210/jc.2016-2999

31. Goichot B, Bouee S, Castello-Bridoux C, Caron P: Survey of clinical practice patterns in the management of 992 hyperthyroid patients in France. Eur Thyroid J. 2017;6(3):152–159. doi: https://doi.org/10.1159/000453260

32. Hegedus L. Thyroid ultrasound. Endocrinol Metab Clin North Am. 2001;30(2):339–360. doi: https://doi.org/10.1016/s0889-8529(05)70190-0

33. Erdogan MF, Anil C, Cesur M, Baskal N, Erdogan G. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid. 2007;17(3):223–228. doi: https://doi.org/10.1089/thy.2006.0104

34. Ralls PW, Mayekawa DS, Lee KP, Colletti PM, Radin DR, Boswell WD, Halls JM. Color-flow Doppler sonography in Graves disease: thyroid inferno. AJR Am J Roentgenol. 1988;150(4):781–784. doi: https://doi.org/10.2214/ajr.150.4.781

35. Bogazzi F, Vitti P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab. 2008;4(2):70–71. doi: https://doi.org/10.1038/ncpendmet0692

36. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L., Poppe K., Pearce S.H. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. European Thyroid Journal. 2018; 7(4): 167-186. doi: https://doi.org/10.1159/000490384

37. Wang J, Zhang R Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br J Radiol. 2017;90(1071):20160836. doi: https://doi.org/10.1259/bjr.20160836

38. Sviridenko NYu, Platonova NM, Molashenko NV, Golitsyn SP, Bakalov SA, Serdyuk SE. Endocrine Aspects Of Amiodarone Therapy In Clinical Practice (Follow-Up And Treatment Algorithm For Patients With Thyroid Dysfunction). Russian Journal of Cardiology. 2012;(2):63-71. (In Russ.)]

39. Yang J, Zhu YJ, Zhong JJ, Zhang J, Weng WW, Liu ZF, Xu Q, Dong MJ. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid. 2016(5);26:627–633. doi: https://doi.org/10.1089/thy.2015.0439

40. Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol. 2004;61(5):589–594. doi: https://doi.org/10.1111/j.1365-2265.2004.02135.x

41. Sviridenko NYu, Koloda DE. Antitireoidnye sredstva. V kn.: Racional'naya farmakoterapiya zabolevanij endokrinnoj sistemy i narusheniya obmena veshchestv: Rukovodstvo dlya praktikuyushchih vrachej / Pod obshch. red. I.I. Dedova, G.A. Mel'nichenko. M.: Litterra, 2013. C. 85–90. (In Russ.)]

42. Laurberg P, Berman DC, Andersen S, Bulow Pedersen I: Sustained control of Graves’ hyperthyroidism during longterm low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid. 2011;21(9):951–956. doi: https://doi.org/10.1089/thy.2011.0039

43. Cooper DS. Antithyroid drugs in the management of patients with Graves’ disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88(8):3474–3481. doi: https://doi.org/10.1210/jc.2003-030185

44. Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. 2010;95(5):2227–2233. doi: https://doi.org/10.1210/jc.2009-2752

45. Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, Montori VM. Antithyroid drugs — the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016;26(8):1144–1145. doi: https://doi.org/10.1089/thy.2016.0222

46. Hallberg P, Eriksson N, Ibanez L, Bondon-Guitton E, Kreutz R, Carva-jal A, et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016;4:507–16

47. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;3:352(9):905–917. doi: https://doi.org/10.1056/NEJMra042972

48. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a populationbased cohort study. Br J Clin Pharmacol. 2014;78(3):619–629. doi: https://doi.org/10.1111/bcp.12336

49. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for reating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:CD003420. doi: https://doi.org/10.1002/14651858.CD003420.pub4.

50. Tagami T, Yambe Y, Tanaka T, Tanaka T, Ogo A, Yoshizumi H, Kaise K, Higashi K, Tanabe M, Shimazu S, Usui T, Shimatsu A, Naruse M. BBGD Study Group. Shortterm effects of beta-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves’ disease. Intern Med. 2012;51(17):2285–2290. doi: https://doi.org/10.2169/internalmedicine.51.7302

51. Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, Schuetz P. Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017;176:87–97

52. Diana T, Krause J, Olivo PD, Konig J, Kanitz M, Decallonne B, Kahaly GJ: Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol. 2017;189:304–309

53. Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS: Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid. 2015;25:12821290

54. Donovan PJ, McLeod DS, Little R, Gordon L. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’disease. Eur J Endocrinol. 2016;175(6):595–603. doi: https://doi.org/10.1530/EJE-16-0527

55. Fomin DK, Sviridenko NYu, Rumyancev PO. Terapiya radioaktivnym jodom. V kn.: Nacional'noe rukovodstvo: Endokrinologiya / Pod red. I.I. Dedova, G.A. Mel'nichenko. M.: GEOTAR-Media, 2016. S. 381-390. (In Russ.)]

56. ICRP, 2000. Pregnancy and Medical Radiation. ICRP Publication 84. Ann. ICRP 30 (1).

57. American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335-46. doi: https://doi.org/10.1089/thy.2010.0403

58. Berg GE, Nyström EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S, Niklasson CA, Norén AH, Westphal OG. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med. 1998;39(2):357–361

59. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf ). 2008;69(3):479–90. doi: https://doi.org/10.1111/j.1365-2265.2008.03222.x

60. Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53(10):1633-51. doi: https://doi.org/10.2967/jnumed.112.105148

61. Ross D.S. (2015) Radioiodine Treatment in Patients with Graves’ Disease. In: Bahn R. (eds) Graves' Disease. Springer, New York, NY. doi: https://doi.org/10.1007/978-1-4939-2534-6_7

62. Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013;23(5):620-625. doi: https://doi.org/10.1089/thy.2012.0258

63. Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Hansen BM, Søe-Jensen P, Hansen JM. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. J Intern Med. 1995;238(6):491–497. doi: https://doi.org/10.1111/j.1365-2796.1995.tb01230.x

64. Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med. 1984;16:311(7):426–32. doi: https://doi.org/10.1056/NEJM198408163110702

65. Fadeyev VV, Drozdovsky ВYa, Guseva ТN, Garbuzov P.L., Buziashvili I.I., Melnichenko G.A. Long-term results of treatment of toxic goiter with radioactive 131I. Problems of Endocrinology. 2005;51(1):3-9. (In Russ.)] doi: https://doi.org/10.14341/probl20055113-9

66. Esfahani AF, Kakhki VR, Fallahi B, Eftekhari M, Beiki D, Saghari M, Takavar A. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs. Hell J. Nucl. Med. 2005;8(3):158–161

67. Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33(6):920–80. doi: https://doi.org/10.1210/er.2012-1030

68. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B. Effects of antithyroid drugs on radioiodine treatment: systematic review and metaanalysis of randomised controlled trials. BMJ. 2007;334(7592):514. doi: https://doi.org/10.1136/bmj.39114.670150.BE

69. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. J Clin Endocrinol Metab. 2001;86(7):3016–21. doi: https://doi.org/10.1210/jcem.86.7.7639

70. Bartalena L, Tanda ML, Piantanida E, Lai A. Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005;153(1):13–14. doi: https://doi.org/10.1530/eje.1.01938

71. Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH. J Clin Endocrinol Metab. 2017;1:102(7):2301–2309. doi: https://doi.org/10.1210/jc.2017-00166

72. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of postthyroidectomy hypocalcaemia. Br J Surg. 2014;101(4):307–320. doi: https://doi.org/10.1002/bjs.9384

73. Guo Z, Yu P, Liu Z, Si Y, Jin M: Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol. 2013;79(5):739–746. doi: https://doi.org/10.1111/cen.12209

74. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 2008;228(3):320–330. doi: https://doi.org/10.1097/00000658-199809000-00005

75. Piantanida E. Preoperative management in patients with Graves' disease. Gland Surg. 2017;6(5):476-481. doi: https://doi.org/10.21037/gs.2017.05.09

76. Troshina EA, Sviridenko NYu, Vanushko VE, Rumyantsev PO, Fadeev VV, Petunina NA. The federal clinical recommendations on diagnostics and treatment of toxic goiter. Problems of Endocrinology. 2014;60(6):67-77. (In Russ.)] doi: https://doi.org/10.14341/probl201460667-77

77. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31(5):702–755. doi: https://doi.org/10.1210/er.2009-0041

78. Yoshihara Noh JY, Watanabe Fukushita M, Matsumoto M, Suzuki N, Hoshiyama A, Suzuki A, Mitsumatsu T, Kinoshita A, Kentaro Mikura K, Yoshimura R, Sugino K, Ito K. Exposure to Propylthiouracil in the First Trimester of Pregnancy and Birth Defects: A Study at a Single Institution. J Endocr Soc. 2021;19;5(3):204. doi: https://doi.org/10.1210/jendso/bvaa204

79. Endokrinnye zabolevaniya i beremennost' v voprosah i otvetah. Rukovodstvo dlya vrachej/pod red. I.I. Dedova, G.A. Mel'nichenko, F.F. Burumkulovoj. Moskva.: E-noto, 2024. 336 s. (In Russ.)]

80. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3):238–249. doi: https://doi.org/10.1016/S2213-8587(13)70086-X

81. Lo JC, Rivkees SA, Chandra M, Gonzalez JR, Korelitz JJ, Kuzniewicz MW. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid. 2015;25(6):698–705. doi: https://doi.org/10.1089/thy.2014.0434

82. Andersen SL, Olsen J, Carle A, Laurberg P. Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish populationbased study. J Clin Endocrinol Metab. 2015;100(3):1164–1171. doi: https://doi.org/10.1210/jc.2014-3588

83. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’disease. Clin Endocrinol. 2016;84(1):115–120. doi: https://doi.org/10.1111/cen.12688

84. Kahaly GJ, Olivo PD. Graves’ disease. N Engl J Med. 2017;376(2):184. doi: https://doi.org/10.1056/NEJMc1614624

85. McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992;2(2):155–159. doi: https://doi.org/10.1089/thy.1992.2.155

86. Abeillon-du Payrat J, Chikh K, Bossard N, Bretones P, Gaucherand P, Claris O, Charrie A, Raverot V, Orgiazzi J, Borson-Chazot F, Bournaud C. Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism. Eur J Endocrinol. 2014;171(4):451–460. doi: https://doi.org/10.1530/EJE-14-0254

87. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N: Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’disease. J Clin Endocrinol. Metab. 2007;92:2157–2162

88. Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K. Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396–2403

89. Seo GH, Kim TH, Chung JH. Antithyroid drugs and congenital malformations: a nationwide Korean cohort study. Ann Intern Med. 2018;168(6):405–413. doi: https://doi.org/10.7326/M17-1398

90. Li H, Zheng J, Luo J, Zeng R, Feng N, Zhu N , Feng O. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PloS One. 2015;10(5):e0126610. doi: https://doi.org/10.1371/journal.pone.0126610

91. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315–389. doi: https://doi.org/10.1089/thy.2016.0457

92. Rubin PC. Current concepts: beta-blockers in pregnancy. N Engl J Med. 1981;305(22):1323–1326. doi: https://doi.org/10.1056/NEJM198111263052205

93. Laurberg P/ Remission of Graves’ disease during anti-thyroid drug therapy: time to reconsider the mechanism? Eur J Endocrinol. 2006;155(6):783–786. doi: https://doi.org/10.1530/eje.1.02295

94. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–78. doi: https://doi.org/10.1056/NEJM199801083380201

95. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733–1738. doi: https://doi.org/10.1056/NEJM199206253262603

96. Tabeeva KI. Klinicheskoe techenie endokrinnoj oftal'mopatii posle hirurgicheskogo lecheniya bolezni Grejvsa. Diss. … k-ta med. nauk. M.$ 2010. S 51–69. (In Russ.)]

97. Chen DY., Schneider PF., Zhang XS., Luo XY, He ZM, Chen TH. Changes in graves’ ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves’ disease from 2 prospective, randomized, open-label, blinded end point studies. Exp Clin Endocrinol Diabetes. 2014;122(1):1-6. doi: https://doi.org/10.1055/s-0033-1358484

98. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM. European Group on Graves Orbitopathy: The 2016 European Thyroid Association/ European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5:9–26. doi: https://doi.org/10.1159/000443828

99. Karlsson F, Dahlberg P, Jansson R, Westermark K, Enoksson P. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol. 1989;121(2):132–141

100. Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrnol Invest. 2015;38:481–487. doi: https://doi.org/10.1007/s40618-015-0257-z

101. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L. Lower dose prednisone prevents radioiodineassociated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010;95:1333–1337. doi: https://doi.org/10.1210/jc.2009-2130

102. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol. 2008;69:943–950. doi: https://doi.org/10.1111/j.1365-2265.2008.03279.x

103. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349–1352. doi: https://doi.org/10.1056/NEJM198911163212001

104. Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M. Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab. 2009;94:3381–3386. doi: https://doi.org/10.1210/jc.2009-0506

105. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM, EUGOGO. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67. doi: https://doi.org/10.1530/EJE-21-0479

106. Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4(3):149–163. doi: https://doi.org/10.1159/000438750

107. Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, et al. Thyroid Studies Collaboration: Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055–2065. doi: https://doi.org/10.1001/jama.2015.5161

108. Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S. The natural history of subclinical hyperthyroidism in Graves’ disease: the rule of thirds. Thyroid. 2016;26(6):765–769. doi: https://doi.org/10.1089/thy.2015.0470

109. Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Kanamoto N, Otani H, Furukawa Y, Teramukai S, Akamizu T. 2016 guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (first edition). Endocr J. 2016;63:1025–1064. doi: https://doi.org/10.1507/endocrj.EJ16-0336

110. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis: thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263–277

111. Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, et al. Japan Thyroid Association: Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid. 2012;22:661–679. doi: https://doi.org/10.1089/thy.2011.0334

112. Isozaki O, Satoh T, Wakino S, Suzuki A, Iburi T, et al. Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol. 2016;84:912–918. doi: https://doi.org/10.1111/cen.12949

113. Erkan ME, Demirin H, Asik M, Celbek G, Yildirim M, Aydin Y, Gungor A, Dogan AS. Efficiency of radioactive I-131 therapy in geriatric patients with toxic nodular goiter. Aging Clin Exp Res. 2012;24:714–717. doi: https://doi.org/10.3275/8759

114. Kang AS, Grant CS, Thompson GB, van Heerden JA. 2002 Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine. Surgery. 2002;132:916–923;discussion 923. doi: https://doi.org/10.1067/msy.2002.128691

115. Albino CC, Graf H, Sampaio AP, Vigario A, Paz-Filho GJ. Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. Expert Opin Investig Drugs. 2008;17:1781–1786. doi: https://doi.org/10.1517/13543780802501325

116. Zakavi SR, Mousavi Z, Davachi B. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun. 2009;30:169–175. doi: 10.1097/MNM.0b013e3283169148.

117. Camargo R, Corigliano S, Friguglietti C, Gauna A, Harach R, et al. Latin American thyroid society. Latin American thyroid society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol. 2009;53:1167–1175. doi: https://doi.org/10.1590/s0004-27302009000900014

118. Akbulut A, Aydinbelge FN, Koca G. Radioiodine Treatment for Benign Thyroid Diseases. In (Ed.), Radionuclide Treatments. IntechOpen. 2017. doi: https://doi.org/10.5772/intechopen.68575

119. Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid. 2004;14:933–945. doi: https://doi.org/10.1089/thy.2004.14.933

120. Wahl RA, Rimpl I, Saalabian S, Schabram J. Differentiated operative therapy of thyroid autonomy (Plummer's disease). Exp Clin Endocrinol Diabetes. 1998;4:78–84

121. Mishra A, Agarwal A, Agarwal G, Mishra SK.Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg. 2001;25:307–310. doi: https://doi.org/10.1007/s002680020100

122. Stoll SJ, Pitt SC, Liu J, Schaefer S, Sippel RS, Chen H. Thyroid hormone replacement after thyroid lobectomy. Surgery. 2009;146:554–558;discussion 558–60. doi: https://doi.org/10.1016/j.surg.2009.06.026

123. Di Donna V, Santoro MG, de Waure C, Ricciato MP, Paragliola RM, Pontecorvi A, Corsello SM. 2014 A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. Thyroid. 2014;24(12):1759-64. doi: https://doi.org/10.1089/thy.2014.0111

124. Matte R, Ste-Marie LG, Comtois R, D'Amour P, Lacroix A, Chartrand R, Poisson R, Bastomsky CH. The pituitary-thyroid axis after hemithyroidectomy in euthyroid man. J Clin Endocrinol Metab. 1981;53:377–380. doi: https://doi.org/10.1210/jcem-53-2-377

125. Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, Dralle H. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg. 2000;24:1335–1341. doi: https://doi.org/10.1007/s002680010221

126. Takats KI, Szabolcs I, Foldes J, Foldes I, Ferencz A, Rimanoczy E, Goth M, Dohan O, Kovacs L, Szilagyi G. The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. Exp Clin Endocrinol Diabetes. 1999;107:70–74. doi: https://doi.org/10.1055/s-0029-1212076

127. Mel'nichenko GA, Larina II. Sindrom tireotoksikoza. Differencial'naya diagnostika i lechenie. Terapevticheskij arhiv. 2018; 90(10):4-13.(In Russ.)] doi: https://doi.org/10.26442/terarkh201890104-13